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Abstract 
 Regulation of gene expression is an essential process in all organisms.  Research within the last 
decade has elucidated the central importance of the Mediator complex in the fundamentals of gene 
expression.  Mediator has been shown to adopt various structural changes when bound to different 
transcriptional activators.  As a part of the NF-κB family of proteins, p65 (RelA) is a diverse 
transcriptional activator highly involved in inflammation and immune response as well as other essential 
signaling pathways.  Mediator and p65 have been shown to interact through the activation domain of 
p65.  To further explore this interaction, the p65-Mediator complex was purified in vitro and analyzed by 
mass spectrometry to identify cofactors of the complex.  Evidence is provided for the identification of 
both novel and previously described interactions.    
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Introduction  
Protein expression requires two distinct processes, transcription and translation.  Transcription 
is the process of synthesizing RNA (ribonucleic acid) from a DNA (deoxyribonucleic acid) template, the 
genetic material of life.  These RNA products are translated into a polypeptide chain. 
There are three major types of RNA that are produced in cells: transfer RNA (tRNA), messenger 
RNA (mRNA), and ribosomal RNA (rRNA), which all work together to carry out the essential process of 
protein synthesis.  My thesis work focused on the machinery involved in the production of mRNA, which 
is the form translated into polypeptides. 
A sequence of mRNA encodes for a defined, unique sequence of amino acids called a 
polypeptide.  Polypeptides are folded into distinct shapes and serve various physiological roles.  The 
synthesis of the polypeptide (translation) occurs at the ribosome, which incorporates the individual 
amino acids into the polypeptide chain.  But before any translation can occur, transcription of the target 
gene must first take place, resulting in the synthesis of the corresponding mRNA. 
Specialization is extremely important for both differentiated and undifferentiated cells, and this 
specialization is accomplished by alterations in gene expression.  For example, heart cells and brain cells 
differ in the proteins that they express, and this difference stems from a difference in the genes that are 
transcribed.  For a certain mRNA to be produced, there are various steps that must occur.  Within the 
nucleus, DNA is packaged by histones into a dynamic higher order structure called chromatin.  Rather 
than simply being a long strand, chromatin is a tightly packed form of DNA.  This structure inhibits the 
ability of the necessary components of transcription to access the gene of interest.  This structure must 
therefore be modified in specific ways in order to make parts of the genome accessible (Li and Reinberg 
2011; Voet and Voet, 2004). 
Once the proper genetic sequence is made available by an activated DNA binding transcription 
factor (activator), the transcription machinery must assemble at the promoter (area just upstream of the 
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transcription start site) specific to the gene of interest.  The transcriptional machinery is made up of RNA 
Polymerase II (RNAP II) and other proteins called transcription factors, of which there are three types.  
General transcription factors are necessary for all forms of transcription.  They function by assembling at 
the gene promoter and serve to recruit RNAP II to the site of initiation, as well as a variety of other 
functions.  Upstream transcription factors do not assemble at the core promoter, but instead bind to 
upstream DNA sequences (enhancers) and function to either activate or repress gene expression.  
Inducible transcription factors are analogous to upstream transcription factors except that they are 
under direct control of other systems (signaling pathways), either functioning to activate or repress 
transcriptional activity.  (Voet and Voet, 2004) 
The assembly of all of the necessary factors is termed the pre-initiation complex (PIC).  At this 
point, initiation can take place and RNAP II will be released from the core promoter and travel along the 
DNA.  As it travels, RNAP II incorporates the appropriate bases and a new mRNA strand is synthesized.  It 
should be noted that further processing is necessary before this strand becomes mature mRNA which is 
capable of being translated by the ribosome. 
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The Mediator Complex 
Mediator is a human transcriptional coactivator that is essential for activated gene transcription.  
It is a 26-subunit 
complex that is 1.2 MDa 
in size.  It has a very 
large surface area for 
protein-protein 
interactions yet has few 
predicted structural 
domains based on amino acid sequence.  Mediator is thought to work by acting as an interface between 
DNA-bound transcription factors and the core promoter (Figure 1).  Activator binding causes structural 
shifts within Mediator, thereby regulating its activity (Taatjes et al., 2002).  This concept has been 
demonstrated with SREBP-1a and VP16-Mediator as shown in Figure 2.  When activator-Mediator 
complexes were compared with the activator-free state, unique cofactors were identified that were 
specific to the activator-bound form of Mediator (Ebmeier and Taatjes, 2010). 
In addition, Mediator has been shown to have activator-independent functions, as seen by basal 
levels of transcription (no activator present).  It has been shown to be involved in RNAP II recruitment 
yet may also function in post-recruitment regulation of RNAP II (Knuesel and Taatjes, 2011).  There is 
also sufficient evidence to suggest that Mediator should in fact be considered a general transcription 
factor due to its importance in transcription as a whole.  Mediator is thought to function at all RNAP II 
promoters (Taatjes, 2010; Kornberg, 2005).   
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Understanding transcriptional 
regulation and gene expression in 
metazoans is very difficult in 
comparison to simple single-cell 
organisms (e.g. yeast) because of the 
greater complexity that each step 
incorporates.  Despite these difficulties, 
recent advances in the bioscience fields 
have allowed further exploration.  It is 
increasingly important to study various 
processes in the context of eukaryotes, 
especially because humans are 
eukaryotic organisms.  Therefore 
research done in this context will be 
able to more directly relate to human health issues (e.g. cancer).   
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The NF-κB Transcription Factor 
The Nuclear Factor-kB (NF-κB) family of 
proteins are small signaling molecules that act as 
inducible transcription factors in mammalian cells.  
NF-κB family members are highly involved in the 
regulation of inflammation and immune response; 
however they are also important for regulation of 
genes that control cell growth and proliferation.  
Dysregulation of NF-κB has been shown to have 
major consequences in health issues such as 
chronic inflammation, immunodeficiency, and 
cancer (Hayden and Ghosh, 2008; Courtois and 
Gilmore, 2006).   
One of the NF-κB proteins is p65.  To form 
an active transcriptional complex, p65 forms a 
heterodimer with p50, another NF-κB family 
member.  When inactive, the p65/p50 dimer is 
found in the cytoplasm of the cell bound to IκB.  IκB 
inhibits the transport of the p65/p50 complex to 
the nucleus by binding in such a way that the nuclear localization signal (NLS) of p65 is no longer 
exposed.  For activation to occur, IκB must be phosphorylated by IκB Kinase (IKK), which causes release 
of the p65/p50 complex and subsequent degradation of IκB through Ubiquitin-dependent proteolysis.  
The NLS is thereby exposed and the dimer translocates to the nucleus where it binds specific DNA 
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elements, recruits coactivators, and displaces repressors in order to activate transcription (Hayden and 
Ghosh, 2008).  The NF-κB signaling pathway is shown in Figure 3.   
With regard to the regulation of gene expression by the p65/p50 heterodimer, the transcription 
activation domain (TAD) of p65 is of the most direct importance, demonstrated by its ability to restore 
transcription activity of 
the full-length protein 
(O’Shea and Perkins, 
2008).  The Rel 
homology domain 
(RHD) is found in all NF-κB proteins and is responsible for DNA binding as well as dimerization (Hayden 
and Ghosh, 2008).  As seen in Figure 4, the activation domain (TAD) is located between residues 428 and 
551 (O’Shea and Perkins, 2008).   
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Hypothesis 
Mediator is known to form a complex with p65 during transcriptional activation (Naar et al., 
1999). Drawing from the data from other activator-Mediator complexes (as discussed above), we 
hypothesize that there are p65-specific cofactors that are bound to Mediator for regulation of activated 
transcription (Figure 2).  The goal of this work is to isolate the p65-Mediator complex and identify 
associated cofactors.  Comparison of p65-associated factors with other transcription factors should help 
identify key proteins that control expression of NF-κB target genes.  These potential “p65-specific” 
cofactors must then be further validated so that conclusions and further hypotheses can be formed.   
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Results 
 The hypothesis and direction for this project came out of two main ideas.  First, p65 has been 
shown to interact with Mediator (Naar et al., 1999; O’Shea and Perkins, 2008).  Secondly, previous data 
from our lab has shown that Mediator undergoes structural shifts in its activator bound state that are 
activator specific.  Furthermore, these states have also been shown to recruit unique sets of cofactors 
(Ebmeier and Taatjes, 2010).  To address this hypothesis the p65-Mediator complex would need to be 
purified with its associated cofactors.   
 Because the activation domain of p65 is responsible activating transcription of target genes, it is 
used here to evaluate the p65-Mediator complex.  Its small size (~120 amino acids) allows for relatively 
straightforward recombinant expression in E. coli.  It is clear from previous data (not shown here) that a 
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high activator concentration is crucial during 
Mediator pull downs from Nuclear Extract.  Starting 
with plasmid DNA coding for GST-p65 TAD (434-
551), expression of the protein was optimized (see 
methods section).  Recombinantly expressed GST-
p65 AD was immobilized on beads and used to pull- 
down Mediator from HeLa nuclear extract.  The 
elution of the GST-p65 pull-down was separated by 
a glycerol gradient (15-40%) to purify the intact 
complex in certain fractions (Figure 5A).  The results 
of the gradient, as well as Mediator content, were 
analyzed by silver stain (SDS-PAGE) and western 
blot.  Silver stain data revealed a clear Mediator 
profile (Figure 5B) in distinct fractions (most 
commonly fractions 11-15), providing validation of 
the strong interaction between the activation 
domain of p65 and the Mediator complex.  Each 
gradient was analyzed individually in order to pool 
fractions that contained the highest amount of the 
Mediator complex.  Western blot data further 
verifies above conclusions from silver stain analysis 
(Figure 5C) as fractions 11 and 13 indicate full assembly of the Mediator complex.  Pooled fractions (5 
from each gradient) were used for analysis by 2-dimensional liquid chromatography coupled to tandem 
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mass spectrometry (2D-LC/MS/MS).  All mass spectrometry work was done by Chris Ebmeier of the 
Taatjes Lab.   
Mass spectrometry was performed in duplicate and the results were searched against the 
human database ipi_v3_75 to provide a list of identified factors (using a 1% false discovery rate).  Two 
runs combined gave 5759 individual peptides.  Each peptide identified equals one spectral count.  The 
data is presented as the number of spectral counts unique to each gene product.  All Mediator subunits 
were identified.  The spectral counts are displayed in Table 1.  CDK19 is a paralog of CDK8 
(Mukhopadhyay et al., 2010).  MED13L is a paralog of MED13.   
In order to address the question of whether there are cofactors that are unique to the p65-
Mediator complex, the data set generated was compared to similar data sets generated in the lab.  By 
comparing p65 data to other activators, it is possible to define p65-only cofactors.  Based on this 
comparison, p65-only factors are defined as being only identified in the presence of p65 and not with 
p53.  Using a cutoff of 5 spectral counts, this produced Table 2.  Data from the three isoforms of SREBP 
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(sterol regulatory element-binding protein), another activator, are shown for comparison purposes.   
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Discussion 
Evidence is compelling from the combination of silver stain, western blot, mass spectrometry 
data, as well as previously published data (Naar et al. 1999; O’Shea and Perkins, 2008) that Mediator is 
interacting with the activation domain of p65.  Further purification (e.g. phosphocellulose column) of 
the nuclear extract, commonly used in laboratory protocols, was not used here to avoid eliminating 
some cofactors of the p65 complex from the purification.  This method therefore allows for a broad 
screen of potential cofactors.   
Under glycerol gradient conditions, complexes are left largely intact and migrate as one whole 
unit.  This method thereby allows for the p65-Mediator complex to be isolated from other non-Mediator 
associated cofactors.  Due to stringent wash conditions (0.5 
M KCl), only associated cofactors with relatively strong 
affinity should remain bound to the complex.  Mass 
spectrometry analysis identified 5759 peptides leading to a 
total of 435 different identified proteins, including every 
Mediator subunit.  Based on this large data set, it can be 
said that the p65-Mediator complex has many further 
interactions with other factors.  Despite even the strongest 
mass spectrometry data, cofactors must hold up to further biochemical validation before firm 
conclusions can be made about the interaction, and new hypotheses generated about its significance.   
As displayed in Table 1, there are two major forms of the Mediator complex found in cells.  Core 
Mediator is made up of all MED subunits except forCDK8, Cyclin C, MED12, and MED13.  CDK8-Mediator 
has the addition of MED12, MED13, Cyclin C, and CDK8 and excludes MED26 (Taatjes, Marr, and Tijan, 
2004).  The CDK8-bound form of Mediator has been shown to inhibit interaction with RNAP II on certain 
promoters, which thereby inhibits transcription (Knuesel et al., 2009).  CDK8-Mediator has also been 
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shown to have positive roles in transcription regulation (Galbraith, Donner, and Espinosa, 2010).  Both 
forms of the Mediator complex are present in the mass spectrometry data; however it is difficult to 
assess which is more commonly associated with the p65 TAD based on this data alone.  Additional 
experiments may help to elucidate the difference between factors associated with the p65-Core 
Mediator complex versus the p65-CDK8-Mediator complex.  These differences may account for unique 
transcriptional events.   Further evidence for the involvement of the p65-Mediator complex in the 
context of regulation of gene expression is provided by the interaction of the complex with RNAP II, 
displayed in Table 3.   
p65-only factors 
From Table 2 come several interesting cofactors.  Cathepsin A and galactosidase (a lysosomal-
associated protective glycoprotein and lysosomal enzyme, respectively) function together to degrade 
cellular waste.  In addition, cathepsin A has been shown to degrade p65/p50 (Masuhara et al. 2009).  
Various regulatory elements are also highlighted here, such as SETD8 (methyltransferase) (Shi et al. 
2007) and TADA2A (transcriptional adapter, SAGA) (Gamper and Roeder, 2008).  All of these proteins 
have not been shown previously to have p65-specific interactions, suggesting either novel or non-
specific binding.  Further biochemical data is needed for verification.   
CDK9 is of particular interest.  In complex with cyclin T1, CDK9 makes up P-TEFb, a positive 
transcription elongation factor.  P-TEFb facilitates elongation by inactivating negative elongation factors 
and modifying the C-terminal domain of RNAP II to allow for more efficient elongation as well as 
cotranscriptional mRNA processing (Kurosu and Peterlin, 2004) Although CDK9 is seen in the SREBP data 
(Table 2), the fact that p53 shows zero spectral counts indicates that CDK9 may be an important factor 
specific to certain activators, such as p65.  In the same vein comes HEXIM1 which is a known regulator of 
P-TEFb (Yik et al., 2003).  Due to the positive effect P-TEFb has on elongation, it is reasonable to suggest 
that recruitment via an activator complex may facilitate transcription of target genes.  Indeed, there has 
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been evidence to suggest that P-TEFb plays an integral role in transcriptional activation by the activator 
VP16 (Kurosu and Peterlin 2004).  Furthermore, P-TEFb has been shown by multiple groups to interact 
with NF-κB proteins, acting to facilitate activation of target genes (Brasier, 2008).  Inhibition of CDK9 was 
shown to inhibit expression of NF-κB target genes (Schmerwitz et al., 2010).  CDK9 has been shown to 
interact with CDK8-Mediator (Donner et al., 2010), however whether or not this association is specific to 
(or enhanced by) p65-CDK8-Mediator or p65-Core Mediator is not known.   
p65-enriched factors 
Another method of examining cofactors of the p65-Mediator complex is by fold enrichment.  A 
comparison is found in Table 4.  In this table the top spectral count hit for the p65 data set, PRKDC, 
appears.  PRKDC is DNA-dependent protein kinase, which has been shown to play a crucial role in NF-κB 
target gene expression through phosphorylation of p50 (Ju et al., 2010).  Its presence here may indicate 
p65-dependent recruitment of PRKDC which in turn helps to activate target gene expression.  Filamin A 
is also of interest as depletion has been directly linked to a reduction in activation of NF-κB target genes 
(Hiyashi and Altman, 2006).   
Furthermore, enrichment data emphasizes potentially novel p65-specific interactions.  TIMM8A 
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and TIMM13 function together as translocases for the mitochondrial membrane (Beverly et al. 2008), 
yet data here indicates that they may also function as part of the transcriptional machinery responsible 
for transcribing NF-κB target genes.  CSRP2 binding protein functions as an adapter as well as an 
acetyltransferase (Guelman et al., 2009).  Acetyltransferases have a well known role in activation of 
transcription due to their ability to modify chromatin.  TRIM24 is involved in transcriptional control of 
p53 target genes by acting to degrade p53 itself (ubiquitin ligase) (Jain and Barton, 2009).  p65-specific 
recruitment of TRIM24 may have implications for regulation of p53.   
  
19 
 
The Proteasome 
The proteasome is responsible for 
degradation of proteins within the cell and 
functions as a crucial piece of the NF-κB signaling 
pathway by degrading IκB.  The majority of 
proteasome subunits were identified in the mass 
spectrometry data set (Table 5).  The alpha and 
beta type subunits, which comprise the core unit 
of the proteasome (20S), were all found to be 
p65-only factors when compared to p53.  Figure 7 
depicts the structure of the proteasome.  The 
p65-specific recruitment of alpha and beta type subunits to the general transcription machinery may 
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have novel and far reaching implications.  The proteasome has been shown to be involved in 
transcriptional activation, functioning to allow transcription factors to associate with the general 
transcription machinery, as well as to eliminate corepressors from the same complex (Walsh and 
Shupnik, 2009).  The proteasome system is also important for regulating turnover and activity of 
transcription factors by use of ubiquitin, a small protein involved in the proteasome pathway (Muratani 
and Tansey, 2003).   
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Future Research 
Of particular interest for future research is 
the interaction between p65-Mediator, CDK9, and 
HEXIM1.  To investigate this interaction further 
orthogonal purifications (utilizes multiple 
biochemically distinct methods in a single 
purification) will be performed.  Purification of the 
p65-Mediator complex (with associated factors) 
will be followed by antibody purification of 
Mediator itself.  This can be achieved by a nuclear extract pull down with GST-p65 TAD (as described 
previously) and subsequent immunoprecipitation (IP) using antibodies for MED1.  The result will be a 
population of Core Mediator and CDK8-Mediator both in the p65-bound state.  Figure 6 displays the 
purification scheme.  This technique can be applied to any of the potential cofactors identified.  The 
antibody used for the IP can also be varied.  This data will give insight into activator-specific interactions 
that may be taking place.   
In vitro transcription assays may be used to examine the relative transcriptional activity in the 
presence of different identified cofactors.  NF-κB reporter assays may also be employed.   
The two degradation pathways, lysosome and proteasome, that were identified will also be 
investigated further to determine their significance in regulation of gene expression.  For example, 
similar experiments to those described above can be carried out with and without the presence of a 
proteasome inhibitor, helping to describe this potentially novel interaction.   
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Experimental Procedures 
*Protease Inhibitors (PIs): 1 mM Sodium Metabisulfite, 1 mM Dithiothreitol, 0.25 mM 
Phenylmethylsulfonyl Fluoride, 1 mM Benzamidine HCl, 1.7 mg Aprotinin/L 
Transformation: Transformation by electroporation into XL1 (sequencing) and Codon Plus BL21 (protein 
expression) electro-competent E. coli cells.  Chill electro-cuvette on ice, thaw bacteria on ice.  Spot 1μL 
GST-p65 TAD plasmid DNA (from Naar Lab) into cuvette, add 50 μL bacteria, insert into BioRad Gene 
Pulser (settings: 0.2 cm electrode, gap=50, volts=2.5, capacitance=25, pulse controller=200 Ω). 
HeLa Cell Cultures: HeLa cells cultured with JMEM (Joklik’s Modification Minimum Eagle Medium). Cells 
harvested at 500,000 cells/mL or above. Wash once with PBSM (1X phosphate-buffered saline, 0.5% 
MgCl2). Swell with Buffer A (10X Buffer A: 100 mM HEPES, 15 mM MgCl2, 100 mM KCl, pH=7.9) 20 
minutes. Dounce 7X with type A dounce homogenizer.  Flash freeze pellet and store at -80°C.   
Nuclear Extract Preparation: Thaw 100L nuclear pellet in water/ice bath. Add 0.9 times pellet volume of 
Buffer C (20mM HEPES, 24% glycerol, 0.4M NaCl, 1.5 mM MgCl2, 0.5M EDTA, pH 7.9) with protease 
inhibitors while stirring at 4°C. Dounce 20 times on 
ice with type B glass homogenizer. Stir at 4°C for 30 
minutes. Spin at 4°C and 15K for 30 minutes. Keep 
supernatant. Dialyze in 4L Buffer D (20 mM HEPES, 
20% glycerol, 100 mM KCl, 2 mM MgCl2, 0.2 mM 
EDTA) + PIs (no aprotinin) to 0.1 M salt. Spin at 4°C 
and 15K for 30 minutes. Flash freeze supernatant 
and store at -80°C.   
Protein Expression: Starter culture.  Streak 2μL 
glycerol stock on LB/Ampicillin (Amp) agar plate.  
Overnight at 37°C.  Prepare 5mL Luria Broth (LB) 
with 100μg Amp/mL and 50μg Chloramphenicol 
(CAM)/mL, inoculate with single colony from 
overnight plate.  Grow at 37°C until saturated 
(approx. 7-8 hours).  Prepare 100mL LB with 100ug 
Amp/mL and 50ug CAM/mL, inoculate with entire 
5mL culture.  Grow overnight at 37°C.  Expression 
Culture.  Prepare 1L LB with 100ug Amp/mL and 50ug CAM/mL, inoculate with 20mL starter culture.  
Grow at 37°C until OD600=0.6-0.8, reduce temperature to 16°C, induce expression with 0.5mM IPTG 
overnight (approx. 21 hours). Harvest and wash with 1X PBS (phosphate-buffered saline) + PIs. Flash 
freeze and store at -80°C.  Development work was carried out to optimize protein expression.  Figure 8 
shows an example of a time course at 16°C.  Overnight expression was determined to be optimum. IPTG 
concentration was varied to increase protein solubility.  Protein was soluble at 0.5 mM IPTG but 
insoluble at 1mM IPTG.   
GSH-Sepharose Immobilization: Thaw 1L BL21 cell pellet on ice with 20mL H/E + PIs.  Lyse cells via 
sonication for 30 seconds (1s ON, 1s OFF) on setting 3, repeat 3 times.  Clarify lysate by centrifugation at 
4°C, 40K rpm, 30 minutes.  Equilibrate 250μL GSH-Sepharose Beads with 10mL H/E + PIs.  Remove buffer 
from beads and transfer cleared lysate to beads.  Rock/roll >3hr (<5hr).  Wash beads 5X with High Salt  
(1M NaCl, 50mM Tris, 5μM EDTA, 10% glycerol by volume, 50mL 10% NP-40 NP-40, 8mM CHAPS) + PIs, 
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2X with H/E (50mM Tris, 0.5M NaCl, 5M EDTA, 
10% glycerol, 25mL 10% NP-40) + PIs, 1X with 
0.15M HEGN (20mM HEPES, 5M EDTA, 10% 
glycerol, 1mL 10% NP-40, 75mM KCl) + PIs.  Remove 
buffer, leaving enough for 1:1 Buffer:Beads.  Figure 
9 shows analysis of immobilization effectiveness.   
Nuclear Extract Pull-Down: (Starting with 1L BL21 
cell pellet) Thaw 4mL Nuclear Extract on ice.  
Centrifuge in 1.5mL tubes at 4°C, 14K rpm, 30 
minutes.  Transfer 1mL NE to ~50μL immobilized 
beads (see immobilization protocol), rock/roll 
overnight.  Wash beads 5X with 0.5M HEGN + PIs 
and 1X with 0.15M HEGN + PIs.  Elute with bead 
volume of 30mM GSH in Tris Elution buffer (0.15M 
salt) >30 minutes.   
Glycerol Gradient: Pour 15-40% linear glycerol gradient in 2mL Beckman centrifuge tube.  Transfer 
eluate (~200μL) to top of gradient.  Spin at 4°C, 55K rpm, 6 hours.  Pipet 100μL fractions.   
Silver Stain: Shake gel in: 250mL 50% methanol 10 minutes, 250mL 5% methanol 10 minutes, 100mL 
35uM DTT 5 minutes, 250mL with 250mg silver nitrate plus 25μL formaldehyde. Rinse 2X with water and 
2X with developing solution (15g sodium carbonate, 250μL formaldehyde in 500mL cold water), develop 
to desired intensity and quench with citric acid monohydrate to neutral pH. Transfer to water.  
Western Blot: Assemble blot with nitrocellulose and acrylamide gel in 1X transfer buffer (10% 
glycine/tris running buffer, 10% methanol). Transfer at 0.25 Amps for 45 minutes. Disassemble and block 
for 30 minutes with milk blocker (5% milk in PBST). Discard blocker and add appropriate primary 
antibody in fresh milk blocker. Rock overnight at 4°C. Wash 4X with PBST, 10 minutes each. Add 
appropriate secondary antibody in fresh milk blocker. Rock 45 minutes at 25°C. Wash 4X with PBST, 10 
minutes each. Add developing solution and expose film at various time lengths.  
Mass Spectrometry:  See Figure 10 for flow chart. Mediator-containing glycerol gradient fractions were 
precipitated at 4°C using 20%(v/v) TCA, 0.067mg/mL insulin and 0.067%(w/v) deoxycholate. Precipitated 
protein pellets were washed twice with -20°C Acetone and air dried. Proteins were trypsin digested 
using a slightly modified Filter-Aided Sample Prep (FASP) protocol (Nat Methods. 2009 May;6(5):359-
62).  Briefly, protein pellets were suspended with 4%(v/v) SDS, 0.1 M Tris pH 8.5, 10 mM TCEP and 
incubated 30m ambient to reduce disulfides. Reduced proteins were diluted with 8M Urea, 0.1M Tris pH 
8.5 and iodoacetamide was added to 10mM and incubated 30m in total darkness. Reduced and 
alkylated proteins were then transferred to a Microcon YM-30 spin concentrator and washed three 
times with 8M Urea, 0.1M Tris pH 8.5 to remove SDS. Three washes with 2M Urea, 0.1M Tris pH 8.5 
were performed then trypsin and 2mM CaCl2 were added and incubated overnight in a 37°C water bath. 
Digested peptides were eluted and acidified with 5%(v/v) formic acid.  
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Peptides were desalted online and fractionated with a 
Phenomenex Jupiter C18 (5μm 300Å; 0.25 x 150mm) column using 
a two dimensional LC/MS/MS method (Agilent 1100). Seven steps 
of increasing acetonitrile (3, 6, 9, 12, 16, 20 and 100%B; A: 20mM 
ammonium formate pH 10, 4% acetonitrile and B: 10mM 
ammonium formate pH 10, 65% acetonitrile) at 5μL/minute eluted 
peptides for a second dimension analysis on a Dionex Acclaim 
PepMap C18 (3μm 100A; 0.075 x 150mm) running a gradient at 
0.2μL/minute from 5 to 25% B in 100 minutes for steps one 
through six and 10 to 30% B in 100 minutes for step seven (A: 4% 
acetonitrile & B: 80% acetonitrile, both with 0.1% formic acid 
pH~2.5). PepMap eluted peptides were detected with an Agilent 
MSD Trap XCT (3D ion trap) mass spectrometer. 
All spectra were searched with Mascot v2.2 (Matrix Sciences) 
against the International Protein Index (IPI) database version 3.75 
with two missed cleavages and mass tolerances of m/z ±2.0 Da for 
parent masses and ±0.8 Da for MS/MS fragment masses. Peptides 
were accepted above a Mascot ion score corresponding to a 1% 
false discovery rate (1% FDR) determined by a separate search of a 
reversed IPI v3.75 database. Peptides were then filtered and 
protein identifications were assembled using in-house software 
(Chris Ebmeier).  
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